Three folks in Norway handled for “unusual symptoms” after AstraZeneca COVID-19 pictures

Three well being employees in Norway who had lately acquired the AstraZeneca COVID-19 vaccine are being handled in hospital for bleeding, blood clots and a low depend of blood platelets, Norwegian well being authorities stated on Saturday.
Norway halted the rollout of the AstraZeneca vaccine on Thursday, following an identical transfer by Denmark. Iceland later adopted go well with.
“We do not know if the cases are linked to the vaccine,” Sigurd Hortemo, a senior physician on the Norwegian Medicines Agency instructed a information convention held collectively with the Norwegian Institute of Public Health.
All three people had been beneath the age of fifty.
The European drugs regulator, the European Medicines Agency (EMA,) would examine the three incidents, Hortemo stated.

“They have very unusual symptoms: bleeding, blood clots and a low count of blood platelets,” Steinar Madsen, Medical Director on the Norwegian Medicines Agency instructed broadcaster NRK.
“They are quite sick…We take this very seriously,” he stated, including that authorities had acquired notification of the circumstances on Saturday.
AstraZeneca stated an evaluation of its security knowledge overlaying reported circumstances from over 17 million vaccine doses given had proven no proof of an elevated threat of pulmonary embolism, deep vein thrombosis or thrombocytopenia – having low ranges of platelets.
“In fact, the reported numbers of these types of events for COVID-19 Vaccine AstraZeneca are not greater than the number that would have occurred naturally in the unvaccinated population,” an organization spokeswoman stated.
Such traits or patterns had been additionally not noticed throughout medical trials for the vaccine, she added.
Before Denmark and Norway stopped their rollout of the AstraZeneca vaccine, Austria stopped utilizing a batch of the pictures whereas investigating a dying from coagulation problems and an sickness from a pulmonary embolism.
The EMA stated on Thursday the vaccine’s advantages outweighed its dangers and that it might proceed to be administered.
Europe is struggling to hurry up a vaccine rollout after supply delays from Pfizer and AstraZeneca, although new circumstances have spiked in some international locations.